Emmanuel Caeymaex - Journey Medical Director
| DERM Stock | USD 3.40 0.14 3.95% |
Director
Mr. Emmanuel Caeymaex is Director of the Company. He has served as Executive Vice President, Immunology Patient Value Unit of UCB S.A., a biopharmaceutical company, since February 2015. Prior to his current role, Mr. Caeymaex served in various positions at UCB or its affiliated companies, including as Vice President, Senior Global Project Leader of the Cimzia Global Patient Solutions team at UCB Biopharma SPRL from June 2011 to February 2015 and as President of UCB Japan Co Ltd. from September 2006 to June 2011 since 2017.
| Age | 46 |
| Tenure | 7 years |
| Address | 9237 East Via de Ventura Boulevard, Scottsdale, AZ, United States, 85258 |
| Phone | 480 434 6670 |
| Web | https://journeymedicalcorp.com |
Journey Medical Management Efficiency
As of the 24th of April 2024, Return On Capital Employed is likely to grow to 0.03, while Return On Tangible Assets are likely to drop (0.07). At this time, Journey Medical's Intangible Assets are very stable compared to the past year. As of the 24th of April 2024, Intangibles To Total Assets is likely to grow to 0.28, while Non Current Assets Total are likely to drop about 16.4 M. Journey Medical's management efficiency ratios could be used to measure how well Journey Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Chenghu Zhu | Aurora Cannabis | N/A | |
| Tuan Dam | Aurora Cannabis | 60 | |
| Kevin Kotler | Avadel Pharmaceuticals PLC | 45 | |
| Henry Stacpoole | Aurora Cannabis | N/A | |
| Brian McCormack | Cresco Labs | N/A | |
| Randy Podolsky | Cresco Labs | N/A | |
| Adam Szweras | Aurora Cannabis | 48 | |
| Ann Rhoads | Evoke Pharma | 52 | |
| Margaret Atkins | Aurora Cannabis | 63 | |
| Roma Khanna | Curaleaf Holdings | 47 | |
| Hai Nguyen | Aurora Cannabis | N/A | |
| Ken Widder | Evoke Pharma | 65 | |
| Kenneth Widder | Evoke Pharma | 65 | |
| Gregory Brown | Aquestive Therapeutics | 64 | |
| Jijing Niu | Aurora Cannabis | N/A | |
| Calvin Roberts | Alimera Sciences | 64 | |
| Guillaume Cerutti | Avadel Pharmaceuticals PLC | 49 | |
| John Snisarenko | Alimera Sciences | N/A | |
| John FisherStamp | Aurora Cannabis | N/A | |
| Scott LLB | Lucy Scientific Discovery | 54 | |
| Nancy Lurker | Aquestive Therapeutics | 60 | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | 0.0074 |
Journey Medical Corp Leadership Team
Elected by the shareholders, the Journey Medical's board of directors comprises two types of representatives: Journey Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Journey. The board's role is to monitor Journey Medical's management team and ensure that shareholders' interests are well served. Journey Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Journey Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Chairman of the Board | ||
| Lindsay Rosenwald, Executive Chairman | ||
| Ian Clements, IR Contact Officer | ||
| Lori LyonsWilliams, Chief Commercial Officer | ||
| Christopher Griffith, Co-Founder and VP of Corporate Devel. and Strategy | ||
| Andrew Zwible, Vice Operations | ||
| David Cohen, Independent Director | ||
| Mark McDade, Director | ||
| Robyn Hunter, Treasurer Sec | ||
| Eugene Bauer, Founder, Chief Medical Officer, Director | ||
| Jaclyn Jaffe, Senior Operations | ||
| Jake Nunn, Independent Director | ||
| Frederick Craves, Independent Director | ||
| CPA CPA, Chief Officer | ||
| Ernest Galvan, VP Strategy | ||
| Claude Maraoui, President, Founder | ||
| Ramsey Alloush, General Secretary | ||
| Matthew Fust, Independent Director | ||
| Kathleen Sebelius, Director | ||
| Emmanuel Caeymaex, Director | ||
| Christopher Horan, Chief Technical Operations Officer | ||
| William Ringo, Independent Director | ||
| Joseph Benesch, Interim Controller | ||
| Robert Nevin, Chief Officer | ||
| Luis Pena, Co-Founder and Executive VP of Product Devel. | ||
| Thomas Wiggans, Co-Founder, Chairman and CEO | ||
| Andrew Guggenhime, CFO and COO |
Journey Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Journey Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | 0.0074 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 60.85 M | ||||
| Shares Outstanding | 13.93 M | ||||
| Shares Owned By Insiders | 29.91 % | ||||
| Shares Owned By Institutions | 9.72 % | ||||
| Number Of Shares Shorted | 148.09 K | ||||
| Price To Earning | (9.50) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Journey Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Journey Medical's short interest history, or implied volatility extrapolated from Journey Medical options trading.
Pair Trading with Journey Medical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Journey Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Journey Medical will appreciate offsetting losses from the drop in the long position's value.Moving against Journey Stock
| 0.77 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.75 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.7 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
| 0.65 | BMY | Bristol Myers Squibb Earnings Call Tomorrow | PairCorr |
| 0.54 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to Journey Medical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Journey Medical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Journey Medical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Journey Medical Corp to buy it.
The correlation of Journey Medical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Journey Medical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Journey Medical Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Journey Medical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Journey Medical Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Journey Stock analysis
When running Journey Medical's price analysis, check to measure Journey Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Journey Medical is operating at the current time. Most of Journey Medical's value examination focuses on studying past and present price action to predict the probability of Journey Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Journey Medical's price. Additionally, you may evaluate how the addition of Journey Medical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Journey Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Journey Medical. If investors know Journey will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Journey Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.21) | Revenue Per Share 4.343 | Quarterly Revenue Growth (0.04) | Return On Assets 0.0074 | Return On Equity (0.21) |
The market value of Journey Medical Corp is measured differently than its book value, which is the value of Journey that is recorded on the company's balance sheet. Investors also form their own opinion of Journey Medical's value that differs from its market value or its book value, called intrinsic value, which is Journey Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Journey Medical's market value can be influenced by many factors that don't directly affect Journey Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Journey Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Journey Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Journey Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.